The Valley Desk

Clinical trial reportClinical lung cancerPublished

Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib

15 of 32 authors shown in byline order.

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Clinical lung cancer
Published
Subject terms
Humans; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Disease Progression; Acrylamides; Aniline Compounds; Pyrimidines; Indoles; Antineoplastic Combined Chemotherapy Protocols; Mutation; Quality of Life; Aged
PubMed ID
41544603
Added to directory
Source checked

Report a correction or request removal